Silo Pharma, Inc. — Form 8-K
Filed October 2, 2026 · analyzed by the 8-K Agent
8-K
▲ Likely positive
significance 72/100
What the filing says
On October 1, 2026, Silo Pharma acquired software assets (Klone brand web-based tools, source code, object code, and related intellectual property) from Norsight Consulting Inc. The consideration was 300,000 common stock purchase warrants with a $1.51 exercise price, 5-year term (exercisable April 1, 2027 through September 30, 2031), and cashless exercise option. Warrants carry a 4.99% beneficial ownership cap (or 9.99% at Norsight's election) and are subject to a 12-month lockup on any resulting shares. Norsight represents exclusive IP ownership, no third-party infringement, and absence of problematic open-source licensing (except identified exceptions on Exhibit B).
Why this rating
Material acquisition expanding product portfolio for micro-cap ($5.3M). 300k warrants at $1.51 ~$453k notional value (8.5% of market cap). Strategic IP asset adds revenue-generating Klone software to pipeline. Counterparty Norsight is minor constraint via lockup and representations, not major risk. Positive but execution-dependent.
Price action (we called it positive)
before filing · preread $1.50 | at our read pending | +10 min pending | +30 min pending | +1 hr pending | +4 hrs pending |
Quotes via Yahoo Finance at capture time; for filings arriving outside market hours the clock starts at the next open. Not investment advice. How accurate are our calls? →
See more from October 2, 2026.
EDGAR·FLOW summarizes public SEC EDGAR filings with automated analysis. Materiality scores and stock-impact predictions are algorithmically generated and are not investment advice. Always verify against the source filing on SEC.gov.